Research suggests that cafestol and kahweol in unfiltered coffee may slow carbohydrate digestion by modulating intestinal alpha-glucosidase, potentially providing a natural alternative to existing diabetes medications with fewer side effects.
Coffee may have a second act beyond caffeine and cholesterol. A review in Discover Chemistry argues that diterpenes in unfiltered coffee, especially cafestol and kahweol, along with their fatty acid esters and oxidised by-products known as caffaldehydes, could help blunt post-meal blood sugar rises by acting on intestinal alpha-glucosidase, an enzyme central to carbohydrate digestion. The authors, Preeti Korram and Trilochan Satapathy of the Columbia Institute of Pharmacy in Raipur, India, suggest this approach could be gentler than acarbose, the established drug in this class, which is often limited by bloating, flatulence and diarrhoea.
Alpha-glucosidase works at the intestinal brush border, where it helps finish the breakdown of starches into glucose. According to the review, acarbose and similar drugs succeed by mimicking sugars and blocking the enzyme’s active site directly. Coffee diterpenes, by contrast, are proposed to work more indirectly. Their bulky, oily structure appears better suited to the enzyme’s surface and the surrounding membrane than to the narrow catalytic pocket itself.
That difference matters. The review says cafestol and kahweol in coffee are usually present as fatty acid esters, which makes them more lipophilic and helps them settle into the membrane-rich environment where the enzyme sits. Rather than switching digestion off, the authors propose that these compounds may alter enzyme shape or flexibility from the outside, slowing activity without completely stopping it. In theory, that could reduce the surge in blood glucose after a meal while avoiding the fermentable carbohydrate build-up that causes gastrointestinal side effects with acarbose.
The fatty acid “tail” attached to these diterpenes may also be important. The review discusses how chain length and saturation could influence how deeply the molecules insert into membranes and how well they interact with protein surfaces. It also highlights caffaldehydes, oxidation products formed during roasting or exposure to oxygen, as potentially more reactive derivatives that may form reversible links with amino acids on the enzyme surface. That could make them stronger modulators than the parent compounds, while still allowing normal function to return.
The idea fits with earlier research showing that cafestol and kahweol are not one-note coffee compounds. Reviews indexed by Springer and the National Library of Medicine describe them as bioactive diterpenes with a wide range of proposed effects, including anti-inflammatory, liver-protective, anti-cancer and anti-diabetic activity. Other studies have also shown that unfiltered coffee contains far more of these diterpenes than paper-filtered brews, which is why preparation method has long mattered for their cholesterol-raising effects.
Even so, the authors are cautious. They stress that the alpha-glucosidase hypothesis is still built mainly on computer modelling, enzyme-structure reasoning and indirect evidence, not direct human proof. They call for more kinetic studies, binding experiments and high-resolution structural work before any health claim can be made. Cafestol itself is also the problem compound responsible for the LDL-raising effect seen with some unfiltered coffees, so any future use would need to balance possible gut benefits against cardiovascular risk. For now, the review is best read as a reminder that coffee’s lipid fraction may be more biologically interesting than it has been given credit for.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
